National Institute of Mental Health; Notice of Closed Meeting, 40844 [2010-17129]
Download as PDF
<![CDATA[
40844
Federal Register / Vol. 75, No. 134 / Wednesday, July 14, 2010 / Notices
specific topic evaluated by the ICH Q4B
process.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the Agency’s current thinking
on this topic. It does not create or confer
any rights for or on any person and does
not operate to bind FDA or the public.
An alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.regulations.gov, https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, or https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/default.htm.
Dated: July 8, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Food and Drug Administration,
HHS.
National Institute of Mental Health;
Notice of Closed Meeting
emcdonald on DSK2BSOYB1PROD with NOTICES
[FR Doc. 2010–17129 Filed 7–13–10; 8:45 am]
Town Hall Discussion With the Director
of the Center for Devices and
Radiological Health and Other Senior
Center Management
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
Jkt 220001
Dated: July 8, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[Docket No. FDA–2010–N–0321]
BILLING CODE 4160–01–S
16:07 Jul 13, 2010
Name of Committee: National Institute of
Mental Health Special Emphasis Panel, HIV/
AIDS Intervention Development.
Date: July 22, 2010.
Time: 9 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call)
Contact Person: Enid Light, PhD, Scientific
Review Officer, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center, 6001
Executive Blvd., Room 6132, MSC 9608,
Bethesda, MD 20892–9608. 301–443–0322.
elight@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review funding
cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Food and Drug Administration
[FR Doc. 2010–17055 Filed 7–13–10; 8:45 am]
VerDate Mar<15>2010
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
ACTION: Notice of public meeting;
request for comments.
The Food and Drug Administration
(FDA) is announcing a public meeting
entitled: ‘‘Town Hall Discussion With
the Director of the Center for Devices
and Radiological Health and Other
Senior Center Management.’’ The
purpose of this meeting is to present the
Center for Devices and Radiological
Health (CDRH) Fiscal Year (FY) 2010
Priorities. In addition, FDA is interested
in engaging in discussions about issues
that are of importance to the medical
device industry.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Date and Time: The public meeting
will be held on October 7, 2010, from
8 a.m. to 12 noon.
Location: The public meeting will be
held at the Hilton Irvine/Orange County
Airport Hotel, 18800 MacArthur Blvd.,
Irvine, CA 92612. The meeting will not
be videotaped or webcast.
Contact: Heather Howell, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Avenue, Bldg. 66, rm. 4320,
Silver Spring, MD 20993, 301–796–
5718, email: heather.howell@fda.hhs.
gov.
Registration and Requests for Oral
Presentations: If you wish to attend the
public meeting, you must register online
at https://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
ucm215113.htm. Those without Internet
access may contact Heather Howell (see
Contact).
Provide complete contact information
for each attendee, including name, title,
company or organization, address,
email, telephone and fax number.
Registration requests must be received
by 5 p.m. on Wednesday, September 22,
2010.
If you wish to make an oral
presentation during any of the
discussions at the meeting (see section
II of this document, Public Meeting),
you must indicate this at the time of
registration. FDA will do its best to
accommodate requests to speak.
Individuals and organizations with
common interests are urged to
consolidate or coordinate their
presentations, and to request time for a
joint presentation. FDA will determine
the amount of time allotted to each
presenter and the approximate time that
each oral presentation is scheduled to
begin.
Registration is free and will be on a
first-come, first-served basis. Early
registration is recommended because
seating is limited. FDA may limit the
number of participants from each
organization based on space limitations.
Registrants will receive confirmation
once they have been accepted. Onsite
registration on the day of the public
meeting will be provided on a spaceavailable basis beginning at 7 a.m.
If you need special accommodations
due to a disability, please contact Susan
Monahan at 301–796–5661 or by email:
susan.monahan@fda.hhs.gov at least 7
days in advance.
Comments: FDA is holding this public
meeting to share information and
discuss issues of importance to the
medical device industry. CDRH is
specifically interested in addressing the
following question: What mechanism(s)
would you prefer or suggest for FDA to
E:\FR\FM\14JYN1.SGM
14JYN1
]]>Agencies
[Federal Register Volume 75, Number 134 (Wednesday, July 14, 2010)]
[Notices]
[Page 40844]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-17129]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel, HIV/AIDS Intervention Development.
Date: July 22, 2010.
Time: 9 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852. (Telephone Conference
Call)
Contact Person: Enid Light, PhD, Scientific Review Officer,
Division of Extramural Activities, National Institute of Mental
Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6132,
MSC 9608, Bethesda, MD 20892-9608. 301-443-0322.
elight@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review funding
cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.242,
Mental Health Research Grants; 93.281, Scientist Development Award,
Scientist Development Award for Clinicians, and Research Scientist
Award; 93.282, Mental Health National Research Service Awards for
Research Training, National Institutes of Health, HHS)
Dated: July 8, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-17129 Filed 7-13-10; 8:45 am]
BILLING CODE 4140-01-P
